Medicaid Pharmaceutical Reimbursement Analysis

This analysis report focuses on Medicaid pharmaceutical reimbursement and aims to identify opportunities for cost savings. The report analyzes the largest portions of Medicaid pharmaceutical costs by drug classes and individual drugs, regional differences in prescription usage and cost, and opportunities for savings. The report finds that the costliest drug class is Insulin followed by classes related to hepatitis B and HIV treatment, type 2 diabetes and obesity, and respiratory diseases. Specific drugs like "Adalimumab" and "bictegravir sodium", "emtricitabine", and "tenofovir alafenamide fumarate" are identified as the most expensive nonproprietary drugs. The report provides insights to inform future public policies and reduce Medicaid costs. It is useful for Medicaid administrators and federal regulators in managing pharmaceutical spending and optimizing resource allocation.